On August 31, 2022 ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, reported that L1 Capital Global Opportunities Master Fund ("L1") has exercised Options over 2,000,000 new ordinary shares of 1p each ("Ordinary Shares") at an exercise price of 5p per share, for a consideration of £100,000 (Press release, ImmuPharma, AUG 31, 2022, View Source [SID1234618820]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New Ordinary Shares and Admission

The New Ordinary Shares have been allotted today and are issued credited as fully paid and will rank pari passu in all respects with the Company’s existing issued ordinary shares.

An application will be made for the New Ordinary Shares to be admitted to trading on the AIM market ("Admission") of the London Stock Exchange. It is anticipated that Admission will occur on or around Monday 5 September 2022.

The New Ordinary Shares represent 0.61% of the Company’s enlarged issued share capital.

Total Shares in Issue

For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies the market that following Admission, the Company’s total issued share capital will consist of 330,403,115 Ordinary Shares with a nominal value of 1p each.

This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.